Significance_NN
of_IN
quantitative_JJ
analysis_NN
of_IN
AML1\/ETO_NN
transcripts_NNS
in_IN
peripheral_JJ
blood_NN
stem_NN
cells_NNS
from_IN
t_NN
-LRB-_-LRB-
8_CD
;_:
21_CD
-RRB-_-RRB-
acute_JJ
myelogenous_JJ
leukemia_NN
._.

Autologous_JJ
peripheral_JJ
blood_NN
stem_NN
cell_NN
transplantation_NN
-LRB-_-LRB-
PBSCT_NN
-RRB-_-RRB-
is_VBZ
replacing_VBG
autologous_JJ
bone_NN
marrow_NN
transplantation_NN
-LRB-_-LRB-
BMT_NN
-RRB-_-RRB-
in_IN
the_DT
treatment_NN
of_IN
leukemia_NN
._.

One_CD
of_IN
the_DT
potential_JJ
advantages_NNS
of_IN
autologous_JJ
PBSCT_NNS
is_VBZ
the_DT
possibility_NN
that_IN
peripheral_JJ
blood_NN
stem_NN
cells_NNS
-LRB-_-LRB-
PBSC_NNS
-RRB-_-RRB-
are_VBP
less_RBR
likely_JJ
to_TO
be_VB
contaminated_VBN
by_IN
leukemic_JJ
cells_NNS
than_IN
bone_NN
marrow_NN
grafts_NNS
._.

However_RB
,_,
the_DT
major_JJ
problem_NN
still_RB
remains_VBZ
the_DT
high_JJ
incidence_NN
of_IN
leukemic_JJ
relapse_NN
following_VBG
autologous_JJ
PBSCT_NNS
,_,
which_WDT
may_MD
be_VB
caused_VBN
by_IN
the_DT
reinfusion_NN
of_IN
PBSC_NNS
contaminated_VBN
by_IN
leukemic_JJ
cells_NNS
._.

Recently_RB
,_,
we_PRP
have_VBP
developed_VBN
a_DT
quantitative_JJ
assay_NN
using_VBG
competitive_JJ
reverse_JJ
transcriptase_NN
polymerase_NN
chain_NN
reaction_NN
that_WDT
estimates_VBZ
the_DT
number_NN
of_IN
AML1\/ETO_NN
transcripts_NNS
in_IN
t_NN
-LRB-_-LRB-
8_CD
;_:
21_CD
-RRB-_-RRB-
acute_JJ
myelogenous_JJ
leukemia_NN
-LRB-_-LRB-
AML_NN
-RRB-_-RRB-
,_,
in_IN
order_NN
to_TO
determine_VB
the_DT
degree_NN
of_IN
leukemic_JJ
cell_NN
contamination_NN
in_IN
PBSC_JJ
harvests_NNS
,_,
and_CC
to_TO
monitor_VB
minimal_JJ
residual_JJ
disease_NN
-LRB-_-LRB-
MRD_NN
-RRB-_-RRB-
quantitatively_RB
in_IN
patients_NNS
with_IN
t_NN
-LRB-_-LRB-
8_CD
;_:
21_CD
-RRB-_-RRB-
AML_NN
._.

Our_PRP$
data_NNS
indicate_VBP
that_IN
although_IN
PBSC_JJ
harvests_NNS
collected_VBN
after_IN
consolidation_NN
chemotherapy_NN
are_VBP
contaminated_VBN
by_IN
leukemic_JJ
cells_NNS
,_,
the_DT
degree_NN
of_IN
leukemic_JJ
cell_NN
contamination_NN
decreases_VBZ
with_IN
repeated_VBN
cycles_NNS
of_IN
chemotherapy_NN
._.

Furthermore_RB
,_,
the_DT
MRD_NN
in_IN
PBSC_JJ
harvests_NNS
is_VBZ
less_RBR
than_IN
in_IN
the_DT
corresponding_JJ
bone_NN
marrow_NN
obtained_VBN
on_IN
the_DT
day_NN
of_IN
the_DT
PBSC_NNS
collection_NN
._.

There_EX
appears_VBZ
to_TO
be_VB
no_DT
relationship_NN
between_IN
the_DT
number_NN
of_IN
AML1\/ETO_NN
transcripts_NNS
found_VBN
in_IN
the_DT
infused_VBN
PBSC_NNS
harvests_NNS
and_CC
the_DT
incidence_NN
of_IN
leukemic_JJ
relapse_NN
following_VBG
autologous_JJ
PBSCT_NNS
in_IN
our_PRP$
study_NN
._.

However_RB
,_,
a_DT
substantial_JJ
decrease_NN
of_IN
AML1\/ETO_NN
transcripts_NNS
was_VBD
seen_VBN
following_VBG
autologous_JJ
PBSCT_NNS
._.

Thus_RB
,_,
the_DT
quantitative_JJ
analysis_NN
of_IN
AML1\/ETO_NN
transcripts_NNS
may_MD
be_VB
clinically_RB
useful_JJ
in_IN
patients_NNS
with_IN
t_NN
-LRB-_-LRB-
8_CD
;_:
21_CD
-RRB-_-RRB-
AML_NN
._.

